People · Operator
Named in public records as an officer, director or promoter · active 2011–2026 · Other, Biotechnology, Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Hockey Parent Holdings, L.P. | — | Other | Series C | $390.8M | $9.2M | 2022 |
| C4 Therapeutics, Inc. | — | Biotechnology | Series C | $70.3M | $2.9B | 2015 |
| Angiocrine Bioscience, Inc. | — | Biotechnology | Series C | $64.2M | $12.1M | 2021 |
| Regenacy Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $28.7M | $142.6M | 2020 |
| ONCoPEP, Inc. | — | Biotechnology | Seed | $12.7M | $153.5M | 2011 |
| Wrinkl, Inc. | — | Other Technology | Seed | $3.5M | $120.1M | 2015 |
Marc Cohen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marc Cohen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William Sullivan | 1 | 13 |
| Paul Finnegan | 1 | 11 |
| John Albright | 1 | 9 |
| William M Sullivan | 1 | 6 |
| Jason Fisherman | 1 | 5 |
| Kenneth Anderson | 1 | 5 |
| Jeff Jonas | 1 | 5 |
| Jeffrey Port | 1 | 4 |
| Jay M. Eastman | 1 | 4 |
| Mark Goodman | 1 | 4 |
| Paul Emery | 1 | 3 |
| David Parkinson | 1 | 3 |
| Richard A. Gulliver | 1 | 2 |
| Elena Prokupets | 1 | 2 |
| David R. Tunnell | 1 | 2 |
| Adam Levyn | 1 | 2 |
| Alex Moskowitz | 1 | 2 |
| Melissa Bodford | 1 | 2 |
| James M. Vogdes | 1 | 2 |
| Martin P. Hughes | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.